Kornimate/medical-research-clean huggingface dataset:
varicocelectomy: can sex-hormones predict improvements in semen quality?

Conditions: Varicocele; Infertility; Semen Quality

Summary: the purpose of this study is to determine if the pre-operative levels of sex-hormones can be used to identify the varicocele patients who can expect improvements in their semen parameters following varicocelectomy.


Eligibility criteria:
inclusion criteria: * varicocele (grade 1-3) and surgery planned for this condition * at least 18 years of age exclusion criteria: * fever within 3 months before the first semen sample * malformations of the uro-genital tract * karyotype other than 46, xy or y micro deletions * endocrine disease * chronic disease * medications which reduce semen quality * epididymitis within 6 months before surgery
development and validation of a survival prediction model for esophageal cancer patients after esophagectomy

Conditions: Survivorship

Summary: in this retrospective study, we analyzed data from the sichuan cancer hospital \& institute esophageal cancer case management database (sch-eccm database) from january 2010 to december 2017. our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (escc) who underwent esophagectomy. using this data, we developed a prediction model for os by considering a combination of clinical characteristics and details of lymphadenectomy variables.

in this retrospective study, we analyzed data from the sichuan cancer hospital \& institute esophageal cancer case management database (sch-eccm database) from january 2010 to december 2017. our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (escc) who underwent esophagectomy. using this data, we developed a prediction model for os by considering a combination of clinical characteristics and details of lymphadenectomy variables. additionally, the receiver operating characteristic curve demonstrated an area under the curve greater than 0.7 at 1, 3, and 5 years in both the verification and training groups. furthermore, kaplan-meier (k-m) curves showed that our model effectively distinguished between high- and low-risk groups (p \< 0.01).

Eligibility criteria:
inclusion criteria: * patients underwent esophagectomy at our hospital. exclusion criteria: * pathology confirmed a non-squamous cell carcinoma, * the tumor was located outside of the thoracic region, * r1/r2 resection was performed indicating incomplete tumor removal, * evidence of distant tumor metastasis was observed, or * they underwent preoperative neoadjuvant therapy

Keywords: survival esophgeal cancer
developing mhealth to promote prep use among thai young men who have sex with men

Conditions: Pre-Exposure Prophylaxis

Summary: the goal of this study is to develop and pilot test technology-based interventions to promote pre-exposure prophylaxis (prep) uptake and adherence among thai young men who have sex with men (ymsm).

motivational enhancement system for adherence (mesa) is a computer-based motivation invention, based on the information-motivation-behavioral skills (imb) model and motivational interviewing (mi) principles, used to promote adherence among hiv-positive youth initiating antiretroviral treatment. in this study, the team will adapt and develop mesa to focus on prep uptake and adherence, which will be called motivational enhancement system for prep uptake and adherence (mes-prep). motivational interactive text messaging (mtm) will be integrated with mes-prep to provide ongoing support to maintain the individual's motivation for behavior change. both interventions will be developed and refined based upon the inputs from ymsm through focus group discussion and youth advisory board. the investigators propose to pilot randomized controlled trial (rct) to evaluate the feasibility, acceptability, and preliminary efficacy of an intervention combining mes-prep and mtm to increase prep uptake and adherence among thai ymsm. eligible ymsm will be randomized to receive either the intervention plus the standard prep counseling or standard prep counseling, and followed for 6 months with assessments at baseline, month 1, 3 and 6.

Eligibility criteria:
inclusion criteria: * age 16-25 years old * men who report sex with men in the past 12 months * confirmed hiv-negative status * self-reported evidence of being at-risk for hiv acquisition, including one of the following in the past 6 months: 1. having a sex with an hiv-positive partner 2. having anal sex 3. without using a condom 4. being diagnosed with an sti or 5. having any illicit drug use (e.g., amphetamine type stimulants) * able to understand, read and speak thai * either having not started prep (group 1: prep naive) or currently on prep but not adherent to prep (taking ≤3 pills/week) in the past month (group 2: prep users). exclusion criteria: * in a mutually monogamous relationship of more than 6 months with a partner who recently tested hiv-negative * have a serious cognitive or psychiatric problem that would compromise ability to provide informed consent * currently enrolled in another hiv intervention study

Keywords: pre-exposure prophylaxis (prep) hiv prevention mobile health (mhealth)
evaluation of hq® matrix medical wound dressing for healing of donor site wounds

Conditions: Donor Site Wound

Summary: the purpose of the study is to evaluate the safety and effectiveness of hq® matrix medical wound dressing for repair of donor site wounds. half of participants will receive hq® matrix medical wound dressing, while the other half will receive sidaiyi® wound dressing.

hq® matrix medical wound dressing is a transparent, non-porous, pliable, gas-permeable, and waterproof film dressing which is comprised of silk fibroin protein of the bombyx mori (b. mori) silkworm. it is intended to provide a moist, gas-permeable and sterile environment to facilitate the normal wound healing process. it is used in the management of non-infected skin defects and various dermal wounds. sidaiyi® wound dressing (suzhou soho biomaterial science and technology co., ltd, suzhou, china) is a cfda approved (su2012-2640182), silk fibroin-based, two-layered spongy dressing. upon the silk fibroin spongy dressing layer is a membrane made of medical silicone. it is used in the management of partial- and full-thickness wounds, donor site wounds and burns. currently, it is the sole silk fibroin biomaterial for wound healing that has received regulatory approval worldwide.

Eligibility criteria:
inclusion criteria: 1. patients, aged from 18 - 60, male or female, with wet wounds or burns, ulcerative skin and soft tissue wound surfaces; 2. the wound surface area ranged from 20cm\^2 to 600cm\^2; 3. the patients had a clear mind and there was no misunderstanding; 4. the patients voluntarily signed the subjects' informed consent form and received timely follow-ups. exclusion criteria: 1. patients with active bleeding in wound surfaces; 2. vasogenic diseases: patients with no blood supply or phlebothrombosis in local wound tissues; 3. those allergic to silk materials; 4. those with serious infection; 5. those with coagulation disorders; 6. those with tumors or diabetes; 7. patients who, according to other doctors' opinion, are unsuitable to use this material for wound treatment.
liquid biopsies in esophageal cancer

Conditions: Esophageal Cancer

Summary: purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (mrd) by using liquid biopsies to measure circulating tumour dna (ctdna) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.

multicentric, retrospective and prospective components. retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. no additional venipunctures are expected. three distinct patient groups are defined, depending on the therapeutic scenario patients undertake: scenario 1: primary resection then follow-up - study-specific liquid biopsies will be collected in 98 patients, at the time of routine labs. samples will be acquired before resection, at 6-8 weeks, 6 and 12 months after resection. scenario 2: chemoradiation followed by resection and follow-up - study-specific liquid biopsies will be collected in 50 patients. samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks, 6 and 12 months after surgery. a subgroup of patients will undertake adjuvant immunotherapy and will constitute group 3. timing of sampling will be adjusted accordingly as per study flowcharts. scenario 3: chemoradiation followed by resection followed by adjuvant immunotherapy - study-specific liquid biopsies will be collected in 100 patients. samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks after surgery and during adjuvant immunotherapy every 3 months including a sample at the end of treatment. patient management is standard of care. no investigational medicinal product (imp) is involved. specific clinicopathological variables will be collected in a redcap electronic case report form and analysed as per statistical analysis plan.

Eligibility criteria:
key inclusion criteria are: 1. male or female, age \> 18 years 2. new diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (escc) or adenocarcinoma (eac) 3. clinically staged - ct1-4 n0-2 m0 (local or locally advanced, resectable) 4. eligible for multidisciplinary treatment as assessed by mdt 5. able to provide informed consent (icf) according to good clinical practice and national/european regulations key exclusion criteria are: 1. (oligo)metastatic disease 2. histologically or cytologically confirmed diagnosis other than squamous cell carcinoma or adenocarcinoma (eg. neuroendocrine carcinoma, lymphoma...) 3. other active malignancies 4. previous exposure to chemoradiation (prior to mdt) 5. treatment plan after mdt: neoadjuvant chemotherapy with no radiation or chemoradiation with definitive intent (surgery is not planned)
exercise and nutrition interventions in age-related sarcopenia

Conditions: Sarcopenia; Muscular Atrophy

Summary: this project will investigate the synergistic effects of aerobic and resistance type exercise, in combination with protein supplementation, on; body composition, musculoskeletal functioning, nutritional status and quality of life in age-related sarcopenia.

musculoskeletal ageing is an inevitable process associated with profound morphological and functional changes that will ultimately transition an individual from independent, to dependable living, relying heavily on personal health care for survival. the united kingdom (uk) population aged over 65 years is expected to rise from 8.8 to 11.3 million by 2025. as life expectancy increases due to advances in medical treatment, an age-related disease termed sarcopenia, has become more prevalent in the elderly. sarcopenia, described as the loss of musculoskeletal mass, strength and/or physical functioning with age, manifests after the 6th decade and rapidly increases after the 8th decade, resulting in a deterioration of health status and quality of life. to manage the looming health and economic consequences of sarcopenia, suitable therapeutic strategies to manage the condition are warranted. therefore, this randomised control trial (rct) will investigate the effects of 16-weeks of exercise and nutritional interventions in inactive senior citizens (60 - 90 years old).

Eligibility criteria:
inclusion criteria: * male and female participants * 60 - 90 years of age * resident in north west, england, uk * bmi 18.5-30 kg/m * can speak and understand english * willing to consent and follow the study procedures exclusion criteria: * recent (i.e. past 3 months) or concurrent participation in any clinical trial or dietary and/or exercise intervention program * self-reported lactose intolerance * uncontrolled diabetes (hba1c \>10) * uncontrolled hypertension (160/100) and uncontrolled hypotension (\<100 systolic) * treatment with beta blockers, calcium channel blockers, digitalis, bronchodilator, * diuretics, vasodilators * current hormone therapy such as insulin, testosterone or hormone replacement therapy * history of falls/osteoporosis * major psychological/mental illness * medical conditions that precluded safe participation in an exercise program * other major systemic diseases: liver and kidney diseases, advanced gastrointestinal disorders, cardiovascular diseases, advanced chronic obstructive pulmonary disease, advanced rheumatoid arthritis, cancer

Keywords: exercise nutrition sarcopenia healthy ageing elderly muscular hypertrophy
intermediate age-related macular degeneration - multimodal analysis and longitudinal study

Conditions: Age-Related Macular Degeneration

Summary: study: observational prospective clinical study. study population: subjects over 55 years old with drusen secondary to intermediate amd. recruitment: at the medical retinal consultation from the ophthalmology department of chulc. primary outcome: identifying imaging predictors of iamd progression.

individuals will be included consecutively and undergo retinal imaging including color fundus photography (cfp), spectral domain optical coherence tomography (sd-oct), oct-angiography (oct-a) using spectralis oct, with oct angiography module (heidelberg eng. gmbh, germany), in order to characterize: a. fundus autofluorescence 1. analyse the correlation between drusen morphology and autofluorescent findings 2. analyse the correlation between outer retinal layers morphology and autofluorescent findings 3. assess anatomic biomarkers of disease progression b. vascular findings 1. test if choriocapillaris perfusion is disturbed in intermediate amd patients; 2. test if retinal capillary plexus perfusion is disturbed in intermediate amd patients: 2.1. analyze superficial retinal capillary plexus (scp), 2.2. analyze deep retinal capillary plexus (dcp); 3. assess if choroidal and retinal vascular changes are related to disease progression.

Eligibility criteria:
inclusion criteria: * to verify the existence of drusen secondary to intermediate amd; soft, cuticular and reticular pseudo-drusen will be considered. * accept and sign the consent. exclusion criteria: * patients are excluded if it is not possible to obtain good quality cfp, sd-oct, oct-a images, if refractive error is ≥±6d or if there is any evidence of accumulation of extracellular fluid, haemorrhage, exudates or fibrosis. * additional exclusion criteria included any history of retinal surgery including laser treatment, signs of diabetic retinopathy, history of retinal vascular occlusion, history of anti-vegf treatment in the study eye or any signs or history of hereditary retinal or macular dystrophy.

Keywords: intermediate amd progression biomarkers late amd sd-oct
the effect of position change on pain and cerebral oxygen saturation

Conditions: Children

Summary: this study is a randomized controlled experimental study to investigate the effect of position change on pain and cerebral oxygen saturation after endotracheal aspiration in pediatric patients.

this study is a randomized controlled experimental study to investigate the effect of position change on pain and cerebral oxygen saturation after endotracheal aspiration in pediatric patients. the study sample consisted of 70 pediatric patients (35 in the control group and 35 in the intervention group) who met the inclusion criteria and whose parents gave informed consent. the research data were collected using the "child identification form" and the "behavioral pain scale". spss 24 program was used to analyze the data obtained in the study. children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration. children in the control group did not receive any treatment.

Eligibility criteria:
inclusion criteria: * pediatric patients whose consent form is signed by their legal guardian * intubated pediatric patients receiving mechanical ventilation support * non-sedatized pediatric patients * pediatric patients who have received only paracetamol and whose duration of action has exceeded 4-6 hours exclusion criteria: * unconscious pediatric patients * pediatric patients receiving pharmacologic drugs other than paracetamol * unstable pediatric patients * pediatric patients with painful procedures during the procedure

Keywords: pediatrics position pain oxygen saturation
a randomised trial comparing supraclavicular block vs supraclavicular and pecs ii block in arteriovenous grafting

Conditions: Arteriovenous Fistula; Arteriovenous Graft; Kidney Failure, Chronic; Renal Failure, End-stage

Summary: this study evaluates the addition of pecs ii block to ultrasound-guided supraclavicular brachial plexus block in patients undergoing arteriovenous graft creation surgery. participants will be randomised into two equal groups, one receiving supraclavicular and pecs ii blocks, the other receiving supraclavicular block and sham block (grade 1).

regional anaesthesia (ra) for arteriovenous grafting surgery has advantages of avoiding risks of general anaesthesia (ga) in this group of patients with significant co-morbidities, and beneficial vasodilatation, which may prevent early fistula thrombosis. hence, ra is preferable to ga for this surgery. brachial plexus blocks (bpb) are the most commonly employed ra technique to anaesthetise the upper limb for this surgery. according to the results of a recent 2-year retrospective audit in our centre, ultrasound-guided supraclavicular bpb are the most popular ra technique for this surgery. anatomically, the t1 and t2 dermatomes are often missed by the supraclavicular bpb. this means that the upper medial arm and axilla (sites involved in brachiobasilic and brachioaxillary arteriovenous grafting) may not be adequately anaesthetised, mandating intraoperative local anaesthetic supplementation by the surgeon. this may affect patients' and surgeons' acceptance of, and satisfaction with the ra technique. the ultrasound-guided pecs ii block, described by blanco et al, seems to address this problem, as the intercostal t1-6, intercostobrachialis, long thoracic nerves and nerve to serratus anterior are targeted by this block.

Eligibility criteria:
inclusion criteria: * patients scheduled for arteriovenous grafting under regional anaesthesia in changi general hospital * american society of anaesthesiologists (asa) physical status 3 to 4 * elective or emergency surgery exclusion criteria: * patients unable to give consent, unable to communicate or cooperate with simple instructions * patients with regular consumption of strong opioids (eg. morphine, oxycodone) or steroids * patients with allergy or contraindications to local anaesthetics or any of the drugs included in this study * patients with pre-existing upper limb neurological deficits * patients who refuse or are unsuitable for regional anaesthesia (eg. severely coagulopathic)

Keywords: brachio-axillary brachio-basilic interfascial plane block pecs ii block supraclavicular brachial plexus block
blood sample collection for experimental blood test to track liver cancer

Conditions: Hepatocellular Carcinoma

Summary: this study investigates if an experimental blood test can help predict how well cancer will remain under control with treatment. ther experimental blood test involves measuring mircornas. micrornas are small molecules which help regulate how genes are expressed. this information may help researchers guide treatment for other patients in the future.


Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form * willing to comply with all study procedures and be available for the duration of the study * definite diagnosis of hepatocellular carcinoma established (by standard radiographic or histologic criteria) * felt to be reasonable candidate for liver transplantation, potentially contingent on success of down-staging therapy exclusion criteria: * either active or recent solid organ cancer other than hepatocellur carcinoma (hcc) within the last 5 years, unless determined by transplant hepatology team not to represent contra-indication to liver transplantation * contra-indication to lrt (as assessed by interventional radiologist, for example severe thrombocytopenia, severe vascular disease precluding access, etc) * history of prior liver transplantation * active or prior systemic therapy for hcc
a clinical pharmacology study of k-877 controlled release tablet

Conditions: Dyslipidemias

Summary: a study to compare the efficacy, safety, and pharmacokinetics of k-877 controlled release tablets with a current normal k-877 tablet in dyslipidemia.


Eligibility criteria:
inclusion criteria: 1. patients with dyslipidemia had to be age 20 years or older at written informed consent(icf) 2. men and postmenopausal women. 3. patients who have received dietary or exercise guidance from 12 weeks prior to screening. 4. patients who have clinical laboratory records with fasting serum tg ≥ 150 mg / dl (or ≥ 200 mg / dl if not fasting) within 6 months before written informed consent. 5. patients with a fasting serum tg ≥ 150 mg / dl at screening. exclusion criteria: 1. patients with a fasting serum tg ≥ 500 mg / dl at screening 2. patients who require administration of prohibited drugs during the clinical trial period after written informed consent 3. patients who have malabsorption or those who have had the history, or who have undergone other surgical procedures that may affect absorption (excluding appendectomy or hernia treatment etc) 4. patients with uncontrolled thyroid disease 5. patients with uncontrolled diabetes as defined by a hba1c(ngsp) ≥ 8.0％ at screening 6. persons with uncontrolled hypertension (sbp ≥ 160 mmhg or dbp ≥ 100 mmhg) 7. patients with an ast or alt three times the upper limit at screening 8. patients with cirrhosis or those with biliary obstruction 9. patients with malignant tumor or those who are judged to have a high risk of recurrence 10. patients who have collected 400 ml or more of whole blood within 16 weeks, or 200 ml or more of whole blood within 4 weeks, or blood samples (plasma and platelet components) within 2 weeks before screening 11. patients with a history of serious drug allergies (anaphylactic shock, etc.) 12. patients with a history of hypersensitivity to pemafibrate, patients who have stopped taking pemafibrate for reasons of insufficient efficacy or safety 13. patients who participate in other clinical trials at the time of written informed consent or who have received clinical trials other than placebo for less than 16 weeks 14. patients who have been determined inappropriate by the investigator or subinvestigator
pupillometry : predictive indicator in external ventricular drain clamping ?

Conditions: Brain Damage; External Ventricular Drain; Hydrocephalus

Summary: pupillar diameter variation to predict success or failure of external ventricular derivation clamping. pupillometry utilisation as a diagnostic tool in external ventricular clamping test in neurological icu should improve patients care in several ways : * earlier use of ventriculo-peritoneal or ventriculo-atrial shunts to shorten the external ventricular treatment duration and thus reduce risks of infection and hospital stay duration * limit the medical imagery prescription and radiation exposition * avoid neurological deterioration linked to the external ventricular drain clamping in case of the pupillometric parameters variation would be earlier than clinical signs


Eligibility criteria:
inclusion criteria: * neurologic icu hospitalization * traumatic brain injury * external ventricular drain exclusion criteria: * legal protection * refusal * therapeutics limitation * craniectomy * pupillar anomaly